JNJ 69095897
Alternative Names: JNJ-69095897Latest Information Update: 23 Jun 2021
At a glance
- Originator Janssen Research & Development
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 10 Jun 2021 Janssen Research & Development plans a phase I pharmacokinetics trial (In volunteers) in Netherlands (PO) (NCT04920578)
- 01 Jun 2021 Thes term addition and mapping request sent, awaiting CTP, the product is not listed on the company website, created profile based on single source, added licensing availability info based on website
- 01 Jun 2021 JNJ 69095897 is available for licensing as of 01 Jun 2021. https://www.janssen.com/belgium/collaboration (Janssen Research & Development pipeline, June 2021)